Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H27NO2.ClH |
| Molecular Weight | 349.895 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC1=CC2=C(C[C@H]3N(CC4CC4)CC[C@@]25CCCC[C@@]35O)C=C1
InChI
InChIKey=QWGXEENWLDBHTR-QGPGBOAMSA-N
InChI=1S/C20H27NO2.ClH/c22-16-6-5-15-11-18-20(23)8-2-1-7-19(20,17(15)12-16)9-10-21(18)13-14-3-4-14;/h5-6,12,14,18,22-23H,1-4,7-11,13H2;1H/t18-,19+,20-;/m1./s1
Oxilorphan (also known as levo-BC-2605) was developed as a long-acting, narcotic antagonist that has agonist properties. Oxilorphan is a partial agonist at the kappa-opioid receptor and antagonist of the mu-opioid receptor. During clinical trials, oxilorphan had led to dysphoria, which combined with its hallucinogenic effects, serves to limit its clinical usefulness. As a result, many patients who experienced these side effects refused to take additional doses in clinical trials.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
42281-48-1
Created by
admin on Fri Dec 15 15:35:52 GMT 2023 , Edited by admin on Fri Dec 15 15:35:52 GMT 2023
|
PRIMARY | |||
|
52305-98-3
Created by
admin on Fri Dec 15 15:35:52 GMT 2023 , Edited by admin on Fri Dec 15 15:35:52 GMT 2023
|
ALTERNATIVE | |||
|
21159630
Created by
admin on Fri Dec 15 15:35:52 GMT 2023 , Edited by admin on Fri Dec 15 15:35:52 GMT 2023
|
PRIMARY | |||
|
4IJ68MD32N
Created by
admin on Fri Dec 15 15:35:52 GMT 2023 , Edited by admin on Fri Dec 15 15:35:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
